China’s homegrown COVID-19 drugs expected for delivery within month after conditional approval
This pill, VV116, is an anti-viral medication for use in adults with mild to moderate COVID symptoms.
Clinical data suggests that the drug can significantly shorten the duration of the disease when compared to placebo, with a lower incidence of adverse effects.
Professor Shen Jingshan and his research team have been developing the drug since January 2020.
The clinical tests and marketing are being conducted by the pharmaceutical company Junshi Biosciences and Vigonvita Life Sciences.
Production of the drug is on the way and the first batches are expected to be delivered within a month.
The new medications have been described as a breakthrough in China’s pharmaceutical industry.
The Shanghai Institute of Materia Medica was also involved in developing the antiviral pill XIANNUOXIN.
__________________
ShanghaiEye focuses on producing top-quality contents.
Nobody knows SHANGHAI better than us.
Please subscribe to us ☻☻☻
______________
1 view
376
98
1 month ago 00:31:54 1
Why USA Soldiers are WAY Stronger Than Chinese Soldiers
2 months ago 00:00:55 1
China’s largest homegrown aircraft carrier CNS Fujian begins maiden sea trial in Shanghai
3 months ago 00:02:01 1
China’s Homegrown AI-powered Interface Speeds up Humanoid Robot Development
3 months ago 00:41:59 1
BEST HULA HOOP Auditions That ASTONISHED The Judges on Got Talent!😱
3 months ago 00:00:58 1
China’s First Homegrown Hydrogen-Powered Urban Train Completes Test